16:24 EST Castle Biosciences (CSTL) sees FY25 revenue $280M-$295M, consensus $269.06M
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CSTL:
- Lake Street raises Castle Biosciences 2025 estimates after Novitas delay
- Castle Biosciences to share data on DecisionDx-SCC
- Castle Biosciences Projects Strong Revenue Growth for 2024
- Castle expects FY24 revenue to meet or exceed top end of $320M-$330M guidance
- Castle Biosciences drops as regional Medicare contractor won’t cover test